Xpress Biologics moves up a gear with Polyplus & SSB

Through this acquisition, Polyplus relies on Xpress Biologics’ ability to manufacture High Quality and GMP grade proteins and plasmids DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies, to leverage the large-scale production of its proprietary plasmid DNA constructs. The French biotech - which aims at enhancing process economies in the advanced therapies sector - is willing to combine expertise in transfection and plasmid DNA engineering and production applied to gene-therapy viral vector manufacturing process to supply GMP grade plasmids as of 2023.

Marc Daukandt, CEO at Xpress Biologics, explains that, thanks to this acquisition by Polyplus, the CDMO is moving up a gear at several levels. First of all, the company will use its optimized expression systems for the clinical production of new biologics in 2023. Another step forward is that Polyplus opens the doors of the global market to Xpress Biologic’ products and technologies. Last but not least, it also enables the Belgian CDMO to contribute to advanced therapy discovery and commercialization forward.